CClinicalTrials.gg
Status unknownNCT03789695RE-ELECTUpdated Mar 26, 2021

RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD

A Phase 4 interventional study of Dabigatran Etexilate in Atrial Fibrillation, T2DM (Type 2 Diabetes Mellitus) and Chronic Kidney Diseases, sponsored by Irina Ermolaeva. Status unknown at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-26.

Sponsored by Irina Ermolaeva · Phase 4, Interventional, and Other

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Kidney function in patients with atrial fibrillation (AF) is tending to decline over a time which is clearly demonstrated in clinical studies. Renal impairment is a risk factor for stroke, its progression is associated with unfavorable prognosis. So preserving kidney function should be considered as a one of priorities when choosing treatment strategies which is especially important in patients with existing chronic kidney disease (CKD) or in patients who have risk of its development. This is especially relevant for the patients with type 2 diabetes mellitus (T2DM) and with CKD who can be considered as a group of risk for rapid kidney function decline.

Read the detailed description

It is suggested that the decline in renal function may occur more slowly in patients receiving dabigatran etexilate (Pradaxa) compared to patients taking warfarin. The planned trial is a prospective phase IV randomized trial in which patients with AF, T2DM and CKD will be randomized to groups receiving either dabigatran etexilate (Pradaxa) or warfarin. The main goal of the study is to assess the differences in annual eGFR reduction between patients receiving dabigatran etexilate (Pradaxa) or warfarin for 24 months. The difference in annual eGFR reduction will be estimated using the SMPI parameters (mixed model of repeated measurements). Secondary goals are as follows: - to evaluate the progression of albuminuria during treatment with dabigatran etexilate (Pradaxa) or warfarin based on the combined endpoint; - to evaluate the dynamics of the albumin/creatinine ratio (ACR) in urine during 2 years of treatment with dabigatran etexilate (Pradaxa) or warfarin; - to evaluate bleeding episodes, acute cerebrovascular accident, and systemic embolism in the dabigatran etexilate (Pradaxa) and warfarin groups; - to compare glycemic control (HbA1c) in patients receiving dabigatran etexilate (Pradaxa) and warfarin

02

Conditions studied

  • Atrial Fibrillation
  • T2DM (Type 2 Diabetes Mellitus)
  • Chronic Kidney Diseases
03

In context

Kidney Diseases

3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.

This study's planned enrollment of 200 is above the median of 70 across 2,640 interventional studies indexed under Kidney Diseases.

Browse Kidney Diseases studies →

Lead sponsor

This is the only study on the registry with Irina Ermolaeva as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Non-valvular atrial fibrillation
  • Diagnosis of T2D according to Russian Clinical Guidelines
  • Chronic kidney disease according to KDIGO definition*
  • Stable RAS background treatment
  • Age > 18 yrs;
  • Informed consent to participate in the study signed by the patient.

Exclusion criteria

Exclusion Criteria:

  • HbA1c >10%
  • UACR > 3000
  • Renal transplant
  • Biopsy proven kidney entities other than Diabetic Kidney Disease (if known only, no kidney biopsy is planned within the study)
  • Background immunosuppressant therapy
  • Hematologic disorders which can influence hemostasis (hemoblastosis, etc.); connective tissue diseases (SLE, systemic scleroderma, dermatomyositis) and any vasculitis;
  • Primary or secondary antiphospholipid syndrome;
  • Known cancer diagnosis;
  • Major surgical interventions within 3 months before the study enrollment and planned for the timelines of the study;
  • Clinically relevant bleeding events within 3 months before the study enrollment;
  • Acute coronary syndrome, PCI or CABG within 12 months before the study enrollment;
  • Hemorrhagic stroke within 12 months before the study enrollment;
  • Organ damages resulted from clinically relevant bleeding within 6 months before randomization
  • Major trauma or any craniocerebral trauma within 30 days before randomization
  • Uncontrolled hypertension (systolic BP>180 and or diastolic BP>100 while on antihypertensive treatment)
  • CHF III-IV functional class (by NYHA)
  • Ischemic stroke within the last 14 days before randomization
  • Concomitant aspirin and/or clopidogrel use;
  • Persistent use of drugs with potential nephrotoxic effects (NSAIDs, cytotoxic drugs etc.);
  • Need in anticoagulation treatment for disease other than AF
  • Pregnancy and lactation;
  • Creatinine clearance \< 30 ml/min (by Cockroft - Gault equation)
  • Thrombocytopenia of \<100 *109 /л
  • Hepatic failure B and C by Child-Pugh score
  • Psychiatrist disorders
  • Background poor compliance
  • Known hypersensitivity to dabigatran, warfarin or their components
  • Life expectancy less than two years
05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Dabigatran etexilate

    Dabigatran etexilate (Pradaxa) 110 mg b.i.d. or 150 mg b.i.d. according SmPC during 2 years

    Drug: Dabigatran Etexilate

  • Active comparator
    Warfarin

    Warfarin under the control of INR once a month (target range 2.0 - 3.0) during 2 years

    Drug: Dabigatran Etexilate

Interventions

  • DrugDabigatran Etexilate

    Study drug dabigatran etexilate. There are two dosage regimens of dabigatran etexilate used in the study: 150 mg b.i.d. and 110 mg b.i.d. The dose of dabigatran etexilate will be chosen by the investigator in accordance with Russian PRADAXA SmPC

    Also known as: Pradaxa

06

What researchers measure

Primary outcomes

  1. Difference in annual eGFR decline (slopes) between dabigatran and warfarin patients

    * eGFR is to be calculated with CKD-EPI equation at baseline and at subsequent major visits. * for primary analysis only eGFR levels at one year and second year of treatment will be used. In case of one of values required for the analysis is missed LOCF (last observational carried forward) approach will be used

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • I.M.Sechenov First Moscow State Medical University (Sechenov University)
    Moscow, 119991, Russian Federation
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03789695
Lead sponsor
Irina Ermolaeva
Responsible party
Irina Ermolaeva (Head of Department of preclinical and clinical trials management, I.M. Sechenov First Moscow State Medical University) — Sponsor-investigator
First posted
Dec 31, 2018
Start date
Nov 14, 2018
Primary completion
Jul 2021 (estimated)
Completion
May 2022 (estimated)
Last update
Mar 26, 2021

Study contacts

Dmitry Napalkov
Contact
dminap@mail.ru
+79104520841
Dmitry Napalkov
principal investigator · First Moscow State Medical University (Sechenov's University)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion